Adult Dosing

Corticosteroid-responsive dermatoses

• Apply sparingly to affected area(s) tid

Pediatric Dosing

Corticosteroid-responsive dermatoses

• >12 yrs: apply sparingly to affected area(s) tid
• Note: Limit use to the least amount compatible with an effective therapeutic regimen

[Outline]

• Adult Dosing
• Pediatric Dosing

• Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• For topical dermatological use only, not for ophthalmic, oral or intravaginal use
• Patients receiving large doses applied to a larger surface area or under occlusive dressings should be evaluated periodically for evidence of HPA axis suppression by using urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, decrease dose quantity/occlusion if clinically appropriate.
• Use the least amount of topical corticosteroid compatible with an effective therapeutic regimen in children, as they are more susceptible to hypothalamic-pituitary-adrenal (HPA) axis suppression, cushing's syndrome, and intracranial hypertension because of a larger skin surface area body weight ratio
• If irritation develops, discontinue the drug and start appropriate therapy
• If dermatological infection occurs, provide appropriate antifungal or antibacterial therapy and temporarily discontinue topical corticosteroid until the infection has been adequately controlled

Cautions: Use with caution in

• Skin infection
• Diabetes mellitus
• Pediatric Population (<12 yrs: safety not established)

Supplemental Patient Information

• Advise patients not to use occlusive dressing unless directed by the physician
• Advise parents of pediatric patients not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area

Pregnancy Category:C

Breastfeeding: Safety unknown; As per manufacturer data, sufficient systemic absorption following topical administration of corticosteroids results in detectable quantity in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have deleterious effect on the infant. Manufacturer advises caution.

• DERM: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneform eruption, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, miliaria
• META: Hyperglycemia
• CNS: Interacranial hypertension
• MISC: Adrenal suppression, cushing syndrome

• Corticosteroid; exact mechanism of action unknown; induces phospholipase A2 inhibitory proteins (lipocortins). These proteins inhibit the release of their common precursor arachidonic acid, thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes
• Minimal systemic availability after topical application. Presence of inflammation and occlusive dressings increase systemic absorption
• Metabolized primarily in liver; CYP450: Unknown
• Renally excreted; minimally in bile
• Half-life: Unknown

US Trade Name(s)

• Cloderm

US Availability

Cloderm

• CRE: 0.1%

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Dermatologic

Dermatologic Topical Agents

Steroids

Pricing data from www.DrugStore.com in U.S.A.

• Cloderm 0.1 % CREA [Tube] (PROMIUS PHARMA)
  45 % = $178.99
  135 % = $506.98

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.